Browse studies

Find your next paid study

7 recruiting studies matching your filters

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration

A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007…

Geographic Atrophy Secondary to Age-related Macular Degeneration

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Apellis Pharmaceuticals, Inc.NCT07215390

Phase 1

A First in Human Phase 1 / 2 Multi-center Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of CTx001 Administered Via a Single Subretinal Injection in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD)…

Geographic Atrophy Secondary to Age-related Macular Degeneration

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Complement TherapeuticsNCT07392255

Observational

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration (i-SIGHT2): a Multicentre, Randomised, Sham-controlled, Double-masked, Clinical Device Trial.

The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients w…

Estimated

~$10 – $1,050

Actual pay is set by the research site.

i-Lumen Scientific AUS PTY LTDNCT06662162

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

This is a non-interventional, observational study to provide insights into the short-term progression of GA secondary to AMD in participants aged ≥55 years. T…

Geographic Atrophy Secondary to Age-related Macular Degeneration

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Complement TherapeuticsNCT07144137

Phase 2

A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and …

Geographic Atrophy Secondary to Age-related Macular Degeneration

Estimated

~$75 – $2,800

Actual pay is set by the research site.

ADARx Pharmaceuticals, Inc.NCT06990269

Phase 1

A Phase 1/2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of an Adeno-associated Virus Vector VV-14295 Administered Suprachoroidally With the Everads Injector In AdultS With GeographIc Atrophy Secondary to Age-related Macular DegeneratiON (the VISION Study)

The goal of this study is to evaluate how safe and tolerable KRIYA-825 (VV-14295) is and to determine how effective it is in reducing the growth of geographic …

Geographic Atrophy Secondary to Age-related Macular Degeneration

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Kriya Therapeutics, Inc.NCT06765980

Phase 2

A Randomized, Double Masked, Placebo-controlled, Multicenter, Dose-range Finding Study to Assess the Efficacy and Safety of FWY003 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Geographic Atrophy Secondary to Age-related Macular Degeneration

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Novartis PharmaceuticalsNCT07441642